Molecular Partners AG (OTCMKTS:MLLCF) Short Interest Down 16.0% in July

Molecular Partners AG (OTCMKTS:MLLCF) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totalling 52,000 shares, a decline of 16.0% from the June 30th total of 61,900 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 520.0 days.

Molecular Partners Stock Performance

Shares of MLLCF stock opened at $5.89 on Tuesday. The firm has a fifty day simple moving average of $6.18 and a 200-day simple moving average of $4.78. Molecular Partners has a twelve month low of $3.40 and a twelve month high of $10.14.

About Molecular Partners

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.